Management
Calvert Research is composed of a group of multi-discipline, senior pharmaceutical and biotechnology professionals experienced in all facets of the Calvert Research business model.
R.C. McLauchlan
Chairman & Chief Executive Officer
Russ McLauchlan founded Calvert Holdings in March 1996 following twenty-six years in the pharmaceutical and biotechnology industry. He has led the company through its acquisition and internal development of key units resulting in an operation capable of providing significant drug testing and development, capital investment, management, and marketing services for emerging biodiscovery and other business organizations.
Prior to founding Calvert, McLauchlan served as president with an early stage pharmaceutical company and a biotechnology company and as an executive with a multinational pharmaceutical/chemical company. He also served as a board member of national and state biotechnology trade associations.
Michael A. Recny, PhD
President
Dr. Recny is a veteran drug developer with more than 25 years experience in the biotechnology industry. During his career, has contributed to the research, development and/or commercialization of three novel drugs that have collectively achieved billions in worldwide sales, and to four other drug candidates that have entered human clinical trials.
Prior to joining Calvert in 2007, Dr. Recny spent 12 years with Trimeris, Inc. as Vice President of Corporate Development where he led Trimeris’ 1997 internal IPO team and made significant contributions to the development and approval of FUZEON®, Trimeris’ first-in-class HIV antiviral. Together with Trimeris’ General Counsel, Dr. Recny structured one of the first 50/50 co-development and profit share partnerships in the industry with Hoffmann-La Roche, Ltd. (1999) to advance FUZEON from Phase II to worldwide approval and commercial launch in 2003. Prior to Trimeris, Dr. Recny was Director of Protein Biochemistry at Procept, Inc. where he helped structure three collaborative R&D agreements with international pharmaceutical companies over a five year period. Earlier in his career, Dr Recny was a Staff Scientist and Laboratory Head at Genetics Institute, Inc. (now a division of Pfizer, Inc.), where his laboratory was the first to publish the complete protein structure and biological characterization of natural and recombinant human erythropoietin.
Dr. Recny attended the University of Rochester as a Joseph C. Wilson Scholar and earned a bachelor’s degree in Biochemistry. He received his Ph.D. in Biochemistry from the University of Illinois, Urbana-Champaign and conducted postdoctoral work through joint academic appointments at the Dana Farber Cancer Institute (Boston, MA) and Harvard Medical School. He has co-authored more than 40 per-reviewed publications and meeting abstracts in the scientific literature.
Andy Burch
Vice President
Founder and President of Carolina Securities, Andy Burch manages the company’s investment banking services and is a principal in Calvert Research. He has spent his career in the fund management and investment banking industry and has served as President of Triangle (North Carolina) Bank, and Senior Vice President of BB&T (North Carolina).
Sam Tetlow
Vice President of Business Development
Sam Tetlow is an experienced life science executive with over 18 years of experience in both operating and investing roles in life sciences and technology fields.
Prior to joining Calvert in 2007, Tetlow was a Partner with Research Triangle Ventures, a North Carolina based venture capital fund that he joined in 2001. While at RTV, he focused on all key aspects of active investing, including selecting investment opportunities, raising capital, participating with management, board leadership and exiting investments. He has participated as a Board Member or business advisor for several RTV portfolio companies, including Gentris Corporation where he serves as Chairman of the Board, Tranzyme Pharma, and Respirics. Through the companies he has invested in, he has participated in four drug or medical technology candidates that advanced from pre-clinical to clinical development.
Tetlow earned a Bachelor of Science in Engineering, with honors, from Worcester Polytechnic Institute and an MBA, with honors, from the Kenan-Flagler Business School, University of North Carolina at Chapel Hill.
Lonnie Bookbinder, PhD
West Coast Regional Director
Dr. Lonnie Bookbinder has worked in the biopharmaceutical industry since 1969 holding multiple positions in pharmaceutical and laboratory sales as well as clinical research before founding his first company, in 1982, providing management and marketing services to doctors, hospitals and companies in the diagnostic and pharmaceutical industry. In 1990, he joined Russ McLauchlan as Director of Business Development at Immunomedics and then held senior VP positions at Nycomed-Salutar, Ribi ImmunoChem and later became COO of CellPath. In 1998, Dr. Bookbinder provided CEO and Board-level guidance to young biotech companies and subsequently co-founded several companies with long-time business associates
In 2007, Lonnie re-joined Russ McLauchlan, founder of Calvert Research, as West Coast Regional Director of Calvert Research, bringing to bear his 38 years of experience in all aspects of product development representing Calvert Research as the strategic partner for universities, researchers and biotech companies with innovative and potentially curative technology and product candidates.
Sara Shen
Business Analyst
Sara Shen is originally from Shanghai, China and holds an MBA and MS degree in Economics from the University of Central Florida. She also has a degree in Applied Mathematics from Tongji University in Shanghai. Sara’s focus at Calvert Research includes research and analysis of potential investments and markets.
